文献速递乳腺病理细胞病理与分子病理

细针穿刺细胞学检测原发与转移性乳腺癌HER2-low状态准确性高

High accuracy in detecting HER2-low status in FNA of primary and metastatic breast cancer.
PubMed 文献 · Cancer Cytopathol · 2026-01-01

该回顾性研究纳入46例乳腺癌细针穿刺(FNA)细胞块,其中原发34例、转移12例,用免疫细胞化学(ICC)评估HER2、ER、PR并与组织学对比。ICC检测HER2-low的灵敏度56.3%-59.4%、特异度85.7%-92.9%,细胞学与组织学一致率超过90%,ROC曲线下面积0.71-0.76。结论认为FNA细胞块在组织标本不可得或有限时是识别HER2-low乳腺癌的可靠工具。

要点

  • FNA细胞块ICC检测HER2-low与组织学一致率超过90%,特异度85.7%-92.9%。
  • HER2-low的ICC灵敏度为56.3%-59.4%,阴性预测值较低(46.2%-50.0%)。
  • ER的ICC与组织学一致性极好,PR为中等一致。

核心结论

  • FNA来源细胞块是组织标本不可得或有限时识别HER2-low乳腺癌的可靠工具,但需标准化评估标准。

研究设计与样本

  • 回顾性研究纳入Vanvitelli大学医院46例乳腺癌FNA细胞块,其中原发34例、转移12例。
  • 由两名病理专家独立进行HER2、ER、PR免疫细胞化学评估,并与对应组织学评估对比。
  • 诊断性能采用灵敏度、特异度、预测值、一致率和ROC曲线分析评价。

主要发现

  • ICC检测HER2-low的灵敏度为56.3%-59.4%,特异度为85.7%-92.9%。
  • 阳性预测值为90.0%-95.0%,阴性预测值为46.2%-50.0%。
  • 细胞学与组织学HER2-low评估一致率超过90%,ROC曲线下面积为0.71-0.76。
  • ER一致性极好,PR为中等一致。

关键数值与推荐

  • HER2-low定义为IHC 1+或2+且无扩增。
  • HER2阳性浸润性乳腺癌占乳腺癌的15%,由ERBB2基因扩增驱动。

临床怎么用

  • 在无法手术或转移性场景中,可用FNA细胞块ICC替代组织学评估HER2-low状态。
  • 需注意ICC检测HER2-low的灵敏度中等且阴性预测值偏低,结果解读应结合临床。

局限性

  • 原文未报告具体局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: HER2-positive invasive breast carcinomas (IBCs) account for 15% of breast cancers and are driven by ERBB2 gene amplification. Although historically associated with aggressive behavior, HER2-targeted therapies have significantly improved outcomes. HER2 status is routinely assessed by immunohistochemistry (IHC) and in situ hybridization (ISH). Recently, tumors with low HER2 expression (IHC 1+ or 2+ without amplification), previously classified as HER2-negative, have emerged as a clinically relevant subgroup. Fine-needle aspiration cytology (FNAC) is a minimally invasive alternative to core needle biopsy, particularly useful in inoperable or metastatic settings. FNAC-derived cell blocks (CBs) allow immunocytochemical (ICC) evaluation of biomarkers. METHODS: This retrospective study included 46 FNAC-derived CBs from breast cancers (34 primary tumors and 12 metastases) collected at Vanvitelli University Hospital. ICC evaluation of HER2, estrogen receptor (ER), and progesterone receptor (PR) was independently performed by two expert pathologists and compared with corresponding histological assessments. Diagnostic performance was evaluated using sensitivity, specificity, predictive values, concordance rates, and receiver operating characteristic (ROC) curve analysis. RESULTS: ICC on FNAC-derived CBs showed good diagnostic performance for HER2-low tumors. Sensitivity ranged from 56.3% to 59.4%, whereas specificity was high (85.7%-92.9%). Positive predictive values reached 90.0%-95.0%, whereas negative predictive values were lower (46.2%-50.0%). Concordance between cytological and histological HER2-low assessment exceeded 90%, with ROC area under the curve values of 0.71-0.76. ER showed excellent concordance, whereas PR demonstrated moderate agreement. CONCLUSIONS: FNAC-derived CBs are a reliable tool for identifying HER2-low breast carcinomas when histological samples are unavailable or limited, emphasizing the need for standardized evaluation criteria.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. D'Abbronzo G, Lucà S, Cozzolino I, et al. High accuracy in detecting HER2-low status in FNA of primary and metastatic breast cancer. Cancer Cytopathol. 2026. PMID: 41757801. doi:10.1002/cncy.70085

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。